86 related articles for article (PubMed ID: 19880164)
1. Maintenance immunotherapy in recurrent ovarian cancer: long term follow-up of a phase II study.
Recchia F; Di Orio F; Candeloro G; Guerriero G; Piazze J; Rea S
Gynecol Oncol; 2010 Feb; 116(2):202-7. PubMed ID: 19880164
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced ovarian cancer.
Recchia F; Saggio G; Cesta A; Candeloro G; Nuzzo A; Lombardo M; Carta G; Rea S
Int J Oncol; 2005 Oct; 27(4):1039-46. PubMed ID: 16142321
[TBL] [Abstract][Full Text] [Related]
3. Phase II randomized study of interleukin-2 with or without 13-cis retinoic acid as maintenance therapy in patients with advanced cancer responsive to chemotherapy.
Recchia F; Saggio G; Cesta A; Alesse E; Gallo R; Necozione S; Rea S
Anticancer Res; 2005; 25(4):3149-57. PubMed ID: 16080579
[TBL] [Abstract][Full Text] [Related]
4. Phase 1B study of subcutaneously administered interleukin 2 in combination with 13-cis retinoic acid as maintenance therapy in advanced cancer.
Recchia F; De Filippis S; Rosselli M; Saggio G; Cesta A; Fumagalli L; Rea S
Clin Cancer Res; 2001 May; 7(5):1251-7. PubMed ID: 11350891
[TBL] [Abstract][Full Text] [Related]
5. Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck.
Recchia F; Candeloro G; Di Staso M; Necozione S; Bisegna R; Bratta M; Tombolini V; Rea S
J Immunother; 2008 May; 31(4):413-9. PubMed ID: 18391754
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in patients with less than complete response to chemotherapy.
Recchia F; Candeloro G; Necozione S; Bisegna R; Bratta M; Rea S
Anticancer Res; 2009 Feb; 29(2):567-72. PubMed ID: 19331204
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer.
Strauss HG; Henze A; Teichmann A; Karbe I; Baumgart A; Thomssen C; Koelbl H
Gynecol Oncol; 2007 Mar; 104(3):612-6. PubMed ID: 17069876
[TBL] [Abstract][Full Text] [Related]
9. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer.
Gronlund B; Høgdall C; Hansen HH; Engelholm SA
Gynecol Oncol; 2001 Oct; 83(1):128-34. PubMed ID: 11585424
[TBL] [Abstract][Full Text] [Related]
10. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.
Bamias A; Koutsoukou V; Terpos E; Tsiatas ML; Liakos C; Tsitsilonis O; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Papatheodoridis G; Archimandritis A; Antsaklis A; Dimopoulos MA
Gynecol Oncol; 2008 Feb; 108(2):421-7. PubMed ID: 18036640
[TBL] [Abstract][Full Text] [Related]
11. The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer.
Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
Gynecol Oncol; 2010 Apr; 117(1):109-16. PubMed ID: 20056267
[TBL] [Abstract][Full Text] [Related]
12. Low dose interleukin-2 and 13-cis-retinoic acid as maintenance therapy in patients with solid tumors responsive to chemotherapy.
Recchia F; Cesta A; Rea S
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):135-43. PubMed ID: 16767920
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
[TBL] [Abstract][Full Text] [Related]
14. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.
Garcia AA; Hirte H; Fleming G; Yang D; Tsao-Wei DD; Roman L; Groshen S; Swenson S; Markland F; Gandara D; Scudder S; Morgan R; Chen H; Lenz HJ; Oza AM
J Clin Oncol; 2008 Jan; 26(1):76-82. PubMed ID: 18165643
[TBL] [Abstract][Full Text] [Related]
15. Prolonged disease control after myeloablative chemotherapy, autologous transplantation and immunotherapy in high-risk early breast cancer.
Recchia F; Candeloro G; Necozione S; Accorsi P; Recchia CO; Tombolini V; Rea S
Anticancer Res; 2010 Jan; 30(1):209-15. PubMed ID: 20150637
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma.
Rose PG; Smrekar M; Fusco N
Gynecol Oncol; 2005 Feb; 96(2):296-300. PubMed ID: 15661211
[TBL] [Abstract][Full Text] [Related]
18. Maintenance immunotherapy in metastatic breast cancer.
Recchia F; Sica G; Candeloro G; Necozione S; Bisegna R; Bratta M; Rea S
Oncol Rep; 2008 Nov; 20(5):1173-9. PubMed ID: 18949418
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-2 and 13-cis retinoic acid in the treatment of minimal residual disease: a phase II study.
Recchia F; De Filippis S; Rosselli M; Saggio G; Fumagalli L; Rea S
Int J Oncol; 2002 Jun; 20(6):1275-82. PubMed ID: 12012010
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
